💜

Caminante no hay camino, se hace camino al andar. Residente de OM 🦀

[MV Chandrakanth @ChandrakanthMv]

🌊 VOLGA | ESMO 2026

A River by Name. A New Course in Bladder Cancer Treatment?

Named after the Volga River — Europe's longest river, flowing through Russia into the Caspian Sea.

Cisplatin-Free. Adjuvant EV-Free.

The Phase III VOLGA trial (N = 695) evaluated perioperative durvalumab ± tremelimumab with neoadjuvant enfortumab vedotin in cisplatin-ineligible or cisplatin-declining MIBC.

🔹 EV + durvalumab: Significant EFS and OS benefit versus surgery-based control.

🔹 Adding tremelimumab: EFS benefit reported; OS not statistically significant at interim analysis.

🔹 Key distinction: EV is given ONLY before surgery — no adjuvant EV!

🔹 FDA: Priority Review granted; decision expected Q4 2026.

The big question: Can shorter EV exposure deliver durable survival benefit with less treatment burden?

Full results awaited at ESMO on 24 October 2026.

📚 Reference: Powles TB et al. VOLGA Phase III trial. ESMO 2026; LBA2. NCT04960709. AstraZeneca, September 2026.

#ESMO26 #VOLGA #BladderCancer #MIBC #EnfortumabVedotin #Durvalumab #UroOncology #MVOnco

[Ojos color sol @ojoscol0rsol]

Yo sin dinero pero con zapatos nuevos porque para eso trabajo:

[•ᒪᑌᑎᗩ• @Lunita_Os]

“Cómo amaneciste?
— Yo…

[𓍯𓂃 @calmgloww]

WITCHES DON'T AGE🕯

[Dr Rishabh Jain @DrRishabhOnco]

🚨 NEW ASCO 2026 GUIDELINE: Recurrent Ovarian Cancer

A practical treatment algorithm worth saving 👇

PLATINUM-SENSITIVE recurrence
→ Platinum doublet remains backbone:
• Carboplatin + PLD
• Carboplatin + paclitaxel
• Carboplatin + gemcitabine
→ Bevacizumab may be added, followed by maintenance bevacizumab
→ Do NOT add trabectedin to PLD

PLATINUM-RESISTANT / REFRACTORY
⭐ FRα-high: Mirvetuximab soravtansine = strong recommendation
Other options:
• PLD
• Paclitaxel
• Bevacizumab + chemotherapy
• Relacorilant + nab-paclitaxel
• Gemcitabine

SURGERY
Secondary cytoreduction is not routinely recommended based on current evidence, but may be discussed when complete gross resection is highly achievable.

HIPEC
Evidence remains insufficient for a routine recommendation.

Key message:
Recurrent ovarian cancer is becoming increasingly biomarker-driven and patient-selected, especially in platinum-resistant disease.

@ASCO @JCO_ASCO @OncoAlert
#OvarianCancer #GynOnc #Oncology

[Luis A. Morgado-MD @DrCriticalCare]

Para que no anden escribiendo
ASA - GOLDMANN

[Lenna ᯓᡣ𐭩 @lennadiary]

ayuda

[Dr Rishabh Jain @DrRishabhOnco]

🌊 Ever wondered why so many durvalumab trials sound like a geography quiz?

After the mountains, durvalumab goes to the seas:

PACIFIC → unresectable stage III NSCLC
Durvalumab after cCRT
5-y OS 42.9% vs 33.4%

CASPIAN → ES-SCLC
Durvalumab + platinum-etoposide
mOS 13.0 vs 10.3 mo
HR 0.73

AEGEAN → resectable NSCLC
Perioperative durvalumab + chemotherapy
EFS HR 0.68
pCR 17.2% vs 4.3%

ADRIATIC → LS-SCLC after cCRT
Durvalumab consolidation
mOS 55.9 vs 33.4 mo
HR 0.73

Four waters. Four landmark trials. One easy way to remember durvalumab. 🌊

📌 Bookmark this before your next thoracic oncology clinic.

@ASCO @oncoalert
#Oncology #LungCancer #Durvalumab #ThoracicOncology

[Diego A. Díaz-García @diegoadiazg]

🎯 Regulation of Immune Checkpoint Molecules.

Tumors evade immune surveillance through complex regulation of immune checkpoint molecules at the genetic, epigenetic, transcriptional, translational, and post-translational levels.

Understanding these mechanisms may improve biomarker development and enable mechanism-guided immunotherapy combinations to overcome resistance.

📖 @NatureRevCancer
DOI 👉🏻 https://t.co/98JjkMBCHX

#CánCare #oncology #immunotherapy #immunecheckpoints

[only sitcom @onlysitcom]

I’m fine.